The powerhouse company delivered a powerhouse earnings report and a powerhouse IPO. ANT reported $33 billion in sales for the nine months ending in September 2026 versus $2.5 billion for 2025 and 41 million in 2023. The $83 IPO price values the company at $1.5 trillion.
I have been a Claude client and user for over a year and consider myself a fan. It has helped me innumerable times with everything from medical advice to investment research to coding. I’m counting on it to cure cancer. At the same time, I am well aware of the threats it poses to our society: jobs, the environment, misuse by enemies, accidents, etc.
Much of these could be at least partially mitigated by effective legislation, yet our government has been asleep at the switch, seduced by the short-term economic benefits, ignoring the risks. Hopefully the recent elections will shake things up. In the meantime, we’re left to trust that the folks behind the curtain will have our best interests at heart. Sigh…
Speaking of Jensen Huang, NVDA declined his offer to return to the scene of the crime. The stock is still faltering.
Otherwise, the bounces we expected across the board have largely occurred. The first big challenge is for indices to rise back above their SMA200s. Until they do, today’s bounce is a backtest and our downside targets remain in force.
Remember this chart from the highs on Oct 6 [see: CIW Oct 6, 2026]:
We’re now getting fairly close…
Stay tuned…









Leave a Reply
You must be logged in to post a comment.